Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

chris.buyse@thrombogenics.com .

Citigate Dewe Rogerson:

Amber Bielecka/ David Dible/ Nina Enegren, Tel: +44(0)207-638-95-71,

amber.bielecka@citigatedr.co.uk

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent in stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reaso
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... White papers by Clinovo on ... technologies, have been published by leading pharmaceutical publications Data ... line of white papers by Clinovo to have been ... Pharmaceutical Online, and OpenHealthNews. , At the request of ... Marc Desgrousilliers, 'The Five Essentials of Cloud Computing ...
(Date:7/29/2014)... July 29, 2014 ... (LBS) zur Erfassung biologischer Daten in Verbindung ... und patentiert. Das LBS nimmt gleichzeitig mehrere ... des Patienten und sucht erhöhte biologische Aktivitäten ... Potenzial, die Entdeckung und Entwicklung neuer Medikamente ...
(Date:7/28/2014)... SAN DIEGO , July 28, 2014 ... algae cultivation technologies, today announced the appointment of biotechnology ... member of the board of directors. Levine replaces Cynthia ... effective immediately. She will remain chairman of the company,s ... leadership on Sapphire Energy,s mission to deliver commercial scale ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 ... China Lubricant Industry” is a professional and ... Lubricant market. The report introduces Lubricant basic ... industry chain structure and industry overview. This ... China’s domestic market as well as global ...
Breaking Biology Technology:Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4
... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTAX: CTIC) ... (the "Letter") from Nasdaq indicating that the Company,s,recently ... Preferred,Stock (the "Series C Preferred") and warrants did ... Nasdaq Marketplace Rule 4351 and IM 4351.,The Nasdaq ...
... Plan Extends Financial Resources Beyond 2008 -, ... Inc. (Nasdaq: SNSS ) today announced that ... and implementing a revised,operating plan that focuses its ... while streamlining the company,s operations and extending,its financial ...
... for Early and Accurate Diagnosis of Peripheral Artery ... Disease ... - Findings Published Online in Circulation -, FREMONT, Calif., Aug. 28 ... research that details how a protein biomarker called beta-2,microglobulin may aid in the ...
Cached Biology Technology:Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination 2Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 2Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 3Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 4Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 2Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 3
(Date:7/29/2014)...  When it comes to technology, healthcare is usually one of ... However, when it comes to wearables, healthcare is trying to move ... Internet of Things and its wearable cousins is less than mature, ... industry, whether it,s in the hospital for a major procedure or ... With that in mind, InformationWeek editor Rodney Brown ...
(Date:7/29/2014)... of Kent has shown for the first time how ... that could have a major impact on cancer therapy ... uncovered the mechanism whereby the physical properties of the ... are ,fine-tuned, to undertake different functions. , While ... providing a framework for the cell, others are more ...
(Date:7/29/2014)... for parents of preterm babies latest research from the ... they become teenagers, the brains of many preterm children can ... A study conducted by the University,s Robinson Research Institute ... experiences no brain injury in early life, their cognitive abilities ... term-born peers. , However, the results of the study, published ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2
... involved in cellular immune signaling, scientists have succeeded in making ... protein with a new twist may eventually be used to ... involved in immune responses that are initiated by proteins called ... the immune system in response to challenges by foreign agents ...
... properties of human bone has been made by scientists ... scientists describe their results –?finding a sort of "glue" ... August issue of the international scientific journal, Nature Materials. ... It describes how healthy bone resists fracture and how ...
... Georgia Institute of Technology and the John Innes Centre ... which disease-causing bacteria may thwart the body's natural defense ... development of more effective antibiotics, appear in the September ... oxide is produced by the body to fight infections. ...
Cached Biology News:Engineered molecule amplifies body's immune response 2Engineered molecule amplifies body's immune response 3Fundamental discovery -- Bone fracture 2Fundamental discovery -- Bone fracture 3Researchers uncover E. coli's defense mechanism 2
Purified anti-DNA-PKcs Phosphorylated (Thr2609)...
Purified anti-PI3K p110 delta...
Biotin anti-mouse Ly-49C/F/I/H...
... Purified Tyrosine Hydroxylase (Ser40) Polyclonal ... raised against synthetic phosphopeptide corresponding ... the phospho-Ser40 of rat Tyrosine ... purified by sequential chromatography on ...
Biology Products: